ASH: Rituximab Leads Way in Older Mantle Cell Patients MedPage Today An induction regimen based on rituximab (Rituxan), followed by rituximab maintenance, now appears to be the best treatment choice for older patients with mantle cell lymphoma. Among those who had initially been treated with R-CHOP, the four-year ... |
